| NCT ID | NCT05456412 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Leiden University Medical Center |
| Condition | Colitis, Ulcerative |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2022-12-20 |
| Primary Completion | 2025-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2022-12-20 with a primary completion date of 2025-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The treatment for Ulcerative Colitis (UC) aims to achieve and maintain remission and is usually lifelong and expensive. Current available medications are unable to break the cycle of chronic inflammation, and still a significant proportion of patients will fail to respond (primary non-response) or lose response over time (secondary non-response). There is now growing evidence that there is substantial interpatient variation in the composition of the inflammation associated network of immune cells. A deeper knowledge of the patient's alterations in the mucosal immune response would help identify key drivers of inflammation and select the appropriate therapy. By analyzing the changes in the composition of immune cells induced by Janus Kinase (JAK) inhibition, we aim to obtain a better insight into the mechanistic effects of JAK inhibition and the downstream effects. These mechanistic insights are needed to identifying potential responders and non-responders in the future.
Eligibility Criteria
Age Ulcerative colitis active disease
Contact & Investigator
Andrea van der Meulen, MD, PhD
PRINCIPAL INVESTIGATOR
Leiden University Medical Center
Frequently Asked Questions
Who can join the NCT05456412 clinical trial?
This trial is open to participants of all sexes, aged 16 Years or older, up to 65 Years, studying Colitis, Ulcerative. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05456412 currently recruiting?
Yes, NCT05456412 is actively recruiting participants. Contact the research team at p.w.voorneveld@lumc.nl for enrollment information.
Where is the NCT05456412 trial being conducted?
This trial is being conducted at Leiden, Netherlands.
Who is sponsoring the NCT05456412 clinical trial?
NCT05456412 is sponsored by Leiden University Medical Center. The principal investigator is Andrea van der Meulen, MD, PhD at Leiden University Medical Center. The trial plans to enroll 60 participants.